Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017 – GlobeNewswire (press release)
|
Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017
GlobeNewswire (press release) Celyad successfully completed the CM-CS1 trial, the first clinical trial using CAR–T NKR-2 cells in relapse refractory patients suffering from Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM). No safety issues were reported and first unexpected … |
